Sandoz spinout last step in Novartis’ transformation into pure-play innovative medicines company

In the midst of a reorganization that is prioritizing multibillion growth drivers and the U.S. market, Novartis has decided to spin out its Sandoz generics business, marking the Swiss pharma’s final step in transforming into an innovative medicines company.

After nearly a year of exploring strategic options for the Sandoz unit, Novartis AG (NYSE:NVS; SIX:NOVN) said Thursday it would commence a 100% spinout of the generics and biosimilars unit, with an expectation the separation would be completed in 2H23...